HealthQuill
About 1.1 billion people globally are living with a mental disorder, mostly anxiety and depression disorders that together accounted for more than two-thirds of such conditions in 2021, according to two reports from the World Health Organization.
Health Pharma Research

‘In 2021, 1.1 billion people worldwide were living with mental disorders’

About 1.1 billion people globally are living with a mental disorder, mostly anxiety and depression disorders that together accounted for more than two-thirds.

Read More
Swedish-British AstraZeneca Plc’s medicine baxdrostat lowered blood pressure in trial patients during an end-stage study, and the company plans to file for regulatory approvals by the end of the year.
Drugs Health Pharma

AstraZeneca’s medicine lowers BP, to file for early approvals

Swedish-British AstraZeneca Plc’s medicine baxdrostat lowered blood pressure in trial patients during an end-stage study, and the company plans to file for regulatory.

Read More
The USFDA has granted a standard approval for Eisai and Biogen's Alzheimer injection, Leqembi —the first treatment to secure the traditional approval, paving the way for wider insurance coverage of the drug.
Drugs

FDA warns Alzheimer patients on Leqembi to seek earlier scanning

HQ Team August 30, 2025: The U.S. Food and Drug Administration (FDA) is recommending an additional magnetic resonance imaging in Alzheimer’s disease patients.

Read More
Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy failed to show “sufficient evidence” of benefit to the patients.
Drugs Health Pharma

J & J stops rheumatoid arthritis trial due to lack of ‘sufficient evidence’

Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in females above 12 years and older, weighing at least 40 kilograms.
Drugs Health Pharma

GSK drug gets Britain’s nod to treat UTI patients 12 years and above

Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in.

Read More
Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.
Drugs Health Pharma

Biogen’s drug to treat postnatal depression gets UK regulator’s nod

Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.

Read More
The Japanese name of the book is an expression used to describe people whom society considers to be failures
Health Opinion Research

The Tomoe test: Self-taught schools need open skies, human touch, peers

A modern home can love a child deeply, but without open skies and rich human interaction, love alone is not enough. Homeschooling can.

Read More
AstraZeneca, Daiichi’s breast cancer drug trial results show improvement in progression-free survival
Health Research

Research reveals first child after age 30 increases breast cancer risk by over 40%

HQ Team August 18, 2025: Research finds that women who have their first child after age 30 face a 40% to 45% higher.

Read More
The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer.
Drugs Health

Implant TAR-200 eliminates bladder cancer in over 80% of high-risk cases in trials

HQ Team August 18, 2025: An implant called TAR-200 has shown remarkable results in treating high-risk bladder cancer. According to a recent Phase.

Read More
Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in people born in 1990 than in 1995, a study reveals.
Drugs Pharma Research

Immunotherapy drug shows promising results against metastatic cancers

HQ Team August 16, 2025: Phase I clinical trial of the CD40 agonist antibody drug 2141-V11, developed by Rockefeller University’s Jeffrey V. Ravetch.

Read More